More layoffs coming to NJ’s pharma sector
Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few months, including Bristol Myers Squibb, Bayer and Johnson & Johnson.
Alzheimer’s drug Leqembi receives full FDA approval
The breakthrough treatment from Eisai and Biogen is the first and only approved to show reduced rates of disease progression and to slow cognitive and functional decline in adults with the disease.
FDA panel unanimously endorses Eisai, Biogen Alzheimer’s drug
The medicine will be used to help early-stage patients with mild cognitive impairment or the mild dementia stage of the debilitating neurodegenerative disease that affects more than 6.5 million Americans.
Eisai’s Alzheimer’s drug receives FDA approval
The medicine is among a new category that works by targeting the root of the disease to reduce sticky clumps of toxic proteins in the brain.
Inside Eisai: SJP completes 300K-square-foot buildout at Nutley HQ (slideshow)
Take a look at the new space, which is home to the pharmaceutical company's approximately 1,200 corporate and R&D employees.
Eisai charts next chapter at iconic site in Nutley
In August, Eisai Inc. cut the ribbon on a 15-story, 332,800-square-foot space that serves as its hub. NJBIZ recently took a tour of this new state-of-the-art center in Nutley.
Eisai cuts ribbon on new US headquarters in Nutley
According to Chairman and CEO Ivan Cheung, the 15-story, 332,800-square-foot space facility at the ON3 Campus, "reinforces our 30-year commitment to New Jersey and signifies the beginning of a new chapter as we establish an ecosystem platform to collaborate with industry, government, medical organizations and the community to deliver breakthrough medicines and new solutions that alleviate the heal[...]
Eisai appoints VP of gov’t affairs and policy
Tricia Brooks will be responsible for guiding, representing and growing the company's work to create a network of bipartisan relationships with key decision makers.










